vapreotidum
Peptideexperimental
Clinical trial activity
2 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00014651)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Somatostatin receptor 3AGONIST
SSTR3 agonist
Somatostatin analogue. Not apporved by FDA, rejected by advisory panel. Not in current company pipeline and no further development reported.
- Somatostatin receptor 2AGONIST
SSTR2 agonist
Somatostatin analogue. Not apporved by FDA, rejected by advisory panel. Not in current company pipeline and no further development reported.
- Somatostatin receptor 5AGONIST
SSTR5 agonist
Somatostatin analogue. Not apporved by FDA, rejected by advisory panel. Not in current company pipeline and no further development reported.
- SomatostatinSupplementation
SST supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)NC1=O- Mol. weight
- 1131.4 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3349523 ↗
- ChEMBLCHEMBL2103975 ↗
Also known as
- bmy-41606
- bmy-41606
- dp-05-094
- dp-05-094
- d-phe-cys-tyr-d-trp-lys-val-cys-trp-nh2
- d-phenylalanyl-cysteinyl-tyrosyl-d-tryptophyl-lysyl-valyl-cysteinyl-tryptophanamide
- octastatin
- rc 160
- rc-160
- rc-160
- rc-160
- vapreotida
- vapreotida
- vapreotide
- vapreotide
- vapreotide
- vapreotide
- vapreotide
- vapreotide acetate
- vapreotide acetate
- vapreotidum
- vapreotidum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00331188 | Phase 3 | May 1, 2006 | Alabama Liver & Digestive Specialists Research Center, CHRISTUS Health, Cornell University, Debiopharm, Harvard University, Indiana University, Johns Hopkins University, Mayo Clinic, Medical University of South Carolina, Mission Health, North Carolina, Northwestern University, University of Alabama, Birmingham, University of California, San Diego, University of Colorado, Denver, University of Kentucky, Virginia Commonwealth University, Washington University in St. Louis, Yale University |
| NCT00014651 | Phase 3 | Mar 1, 2001 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (19)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 2 | 1 | 1 | 2001 |
| Alabama Liver & Digestive Specialists Research Center | Academic/Hospital | 1 | 0 | 1 | 2006 |
| CHRISTUS Health | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Debiopharm | For profit | 1 | 1 | 1 | 2006 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Mission Health, North Carolina | Academic/Hospital | 1 | 0 | 1 | 2006 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2001 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Kentucky | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2006 |
19 organizations
Page 1 / 1